SeamlessBio — Ph. Eur. · ICH Q5A · GMP Documentation · Batch Reservation
Fetal Bovine Serum for Pharmaceutical Applications — Ph. Eur. & EMEA Tested
Pharmaceutical manufacturing and GMP-grade bioprocessing place significantly higher demands on FBS than research applications. Regulatory submissions require documented serum origin, adventitious agent testing to Ph. Eur. and USP standards, TSE risk assessment, and lot reservation to ensure manufacturing consistency from process development through clinical batch production.
Buy fetal bovine serum (FBS) from EU stock
Request a quote or a free test sample – EU stock, no minimum order, lot reservation up to 36 months.
Available Origins
| Origin | TSE Risk Classification | Primary Use Case |
|---|---|---|
| United States | USDA-regulated; negligible BSE risk per EMA/CHMP/BWP | FDA IND/BLA submissions; US-origin preference for USFDA-regulated products |
| Australia | Negligible BSE risk; APVMA-regulated | EMA submissions; lowest TSE risk documentation burden; preferred for EU MAA |
| New Zealand | Negligible BSE risk; MPI-regulated | EMA submissions; equivalent TSE profile to Australia; EU MAA preferred |
| EU Origin | Controlled BSE risk; EU-regulated herd surveillance | EMA submissions requiring EU-origin preference; simplified import documentation for DACH customers |
Pharmaceutical-Grade Specifications
| Parameter | Standard | Available Grade |
|---|---|---|
| Sterility | Ph. Eur. 2.6.1 / USP <71> | All pharma-grade lots |
| Mycoplasma | Ph. Eur. 2.6.7 / USP <63> | All pharma-grade lots |
| Endotoxin (LAL) | Ph. Eur. 2.6.14 / USP <85> | <1 EU/mL (Low Endotoxin grade) |
| Viral safety (BVDV, BVV) | Ph. Eur. 5.2.3 / ICH Q5A | Lot-specific viral testing; PCR and infectivity methods |
| Haemoglobin | Spectrophotometric | <20 mg/dL standard; lower on request |
| Gamma irradiation | ≥25 kGy minimum absorbed dose | On request; dose mapping certificate included |
| Heat inactivation | 56°C / 30 min | On request; complement activity confirmed <10% |
Documentation Package
Every pharmaceutical-grade FBS lot includes a complete documentation package aligned with EMA CHMP/BWP and FDA regulatory expectations:
| Document | SeamlessBio | Regulatory Requirement |
|---|---|---|
| Certificate of Analysis (CoA) | ✅ Per lot | FDA 21 CFR Part 211, EMA Eudralex Vol. 4 |
| Certificate of Origin (CoO) | ✅ Per lot | Raw material traceability |
| TSE/BSE Risk Assessment | ✅ Per lot | EMA CHMP/BWP/457920/2012 |
| Viral Safety Testing Report | ✅ Per lot — BVDV, BVV, REO-3 per Ph. Eur. 5.2.3 | ICH Q5A — viral safety of biological raw materials |
| Gamma Irradiation Certificate | ✅ On request — irradiator validation, dose mapping, absorbed dose confirmation | Single-use bag sterility documentation |
| Animal-Derived Components Declaration (ADCD) | ✅ On request | For regulatory submissions requiring ADCD |
| Batch reservation | ✅ 12–36 months for ATMP/GMP manufacturing campaigns | Process validation — same lot for entire campaign |
Available Specialty Grades for Pharma
| Grade | Key Specification | Pharma Application |
|---|---|---|
| FBS Low Endotoxin | <1 EU/mL | GMP cell culture; minimises pyrogenic risk in manufacturing media |
| FBS Gamma Irradiated | ≥25 kGy, dose-mapped | BSL-2/3 viral vaccine production; enhanced viral safety margin |
| FBS Tet-Free | Tetracycline <10 ng/mL | Inducible expression systems (AAV, lentiviral packaging, CAR-T) |
| FBS Ultra Low IgG | IgG <5 µg/mL | Downstream purification — reduces bovine IgG co-elution on Protein A columns |
| FBS Heat Inactivated | 56°C / 30 min | Complement-sensitive manufacturing processes; T cell expansion |
Frequently Asked Questions
Which FBS origin is preferred for EMA submissions?
Australian and New Zealand origin FBS carries the strongest TSE/BSE documentation for EMA submissions — both countries are classified as OIE Negligible Risk with no indigenous BSE. EDQM CEP is available for both origins. EU-origin FBS is also accepted and can simplify import documentation for DACH-based manufacturers. US-origin FBS (USDA 9CFR) is preferred for FDA IND/BLA submissions.
How long can I reserve a pharmaceutical FBS lot?
SeamlessBio offers batch reservation for 12–36 months for ATMP, GMP manufacturing, and clinical vaccine production programmes — covering the full journey from process development through Phase I/II clinical batch production. This ensures the same lot specification throughout the campaign without risk of gap or lot change that would trigger process re-validation.
Is gamma-irradiated FBS required for GMP viral vaccine production?
Gamma irradiation (≥25 kGy) is not universally mandated but is increasingly specified for GMP viral vaccine production in BSL-2/3 facilities to provide an additional assurance of viral safety beyond standard adventitious agent testing. SeamlessBio provides gamma-irradiated FBS with full dose mapping certificate and validation documentation per ISO 11137. This is also specified in some WHO and ICH Q5A-aligned FBS procurement guidelines.
Why is FBS Tet-Free needed for inducible expression systems?
Standard FBS contains tetracycline residues at 10–100 ng/mL from routine antibiotic use in bovine husbandry. Tet-On and Tet-Off inducible promoter systems — used in AAV packaging cell lines, lentiviral vector production, and CAR-T construct systems — are suppressed by tetracycline at concentrations as low as 1–10 ng/mL. Standard FBS can partially or completely suppress inducible transgene expression, causing researchers to incorrectly conclude their construct is non-functional. FBS Tet-Free <10 ng/mL is mandatory for any Tet-regulated application.
Pharmaceutical FBS — Documentation Package on Request
Full Ph. Eur. specification, origin certificates, viral testing reports, TSE/BSE statements and gamma irradiation certificates available per lot. Batch reservation 12–36 months for GMP programmes.
Email: info@seamlessbio.de | +49 851 37932226
English
Deutsch